ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1068

Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts

Sabrina Fechtner1, Anil K. Singh1 and Salahuddin Ahmed1,2, 1Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, 2Division of Rheumatology, University of Washington, Division of Rheumatology, School of Medicine, Seattle, WA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cannabinoid, Fibroblasts, Inflammation, pain and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, October 22, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: The endocannabinoid system (ECS) is comprised of two evolutionary conserved cannabinoid receptors 1 and 2 (CB1 and CB2) which participate in pain management through Gαi/o mediated signaling. Recent studies show that the expression of CB2, not CB1, is upregulated at both the mRNA and protein levels in rheumatoid arthritis synovial fibroblasts (RASFs) as compared to normal synovial fibroblasts, however, the role the ECS receptors in pro-inflammatory cytokine signaling in RASFs remains poorly understood. In the present study, we used a selective agonist of CB2 (JWH-133) to characterize the role of CB2 activation in interleukin-1β (IL-1β)-induced inflammation in human RASFs.

Methods: Human RASFs were obtained from patients diagnosed with RA according to the ACR guidelines (8 female, 2 male, average age 47.7 ± 5.7 years). Human RASFs were pre-treated with JWH-133 (10-20 µM) for 10 minutes prior to the addition of IL-1β (10 ng/mL) stimulation for 30 minutes for signaling studies or for 24 hours to evaluate the inflammatory mediators. The role of CB2 in IL-1β signaling was examined by employing a small interfering RNA (siRNA) method or using overexpression plasmid specific for CB2. Conditioned media was used for the quantification of IL-6 and IL-8 by ELISA and cell lysates were prepared for the analysis of IL-1β signaling proteins and nuclear translocation of transcription factors NF-κBp65 or AP-1 using Western immunoblotting. To study protein-protein interactions, RASFs treated with JWH-133 or IL-1β were incubated with TAK-TAB_V5 protein. Associated partners were pulled down by immunoprecipitation of V5 beads and analyzed using a Western blotting method.

Results: Pretreatment of JWH-133 exacerbated IL-1β-induced IL-6 and IL-8 production by 21% and 12%, respectively, in human RASFs (p<0.05; n=3). Furthermore, we observed that JWH-133 selectively increased the expression of IL-1β-induced Cox-2 by >2-fold (p<0.05; n=3), suggesting a proinflammatory role of CB2 in IL-1β signaling in human RASFs. Knockdown of CB2 using siRNA inhibited IL-1β-induced IL-6 and IL-8 production by more than 50% and completely abrogated Cox-2 expression in RASFs (p<0.05; n=3). In contrast, the overexpression of CB2 further increased IL-1β-induced IL-6 and IL-8 by approximately 3-fold and 4-fold, respectively (p<0.05; n=3), confirming its proinflammatory role in RASF mediated pain and inflammation. Analysis of immunoprecipitation studies revealed that CB2 associates with active TAK1 upon JWH-133 stimulation to coordinate with IL-1β signaling pathways as observed with an increased nuclear translocation of NF-κBp65 and AP-1.

Conclusion: Our study provides novel evidence that CB2 elicits proinflammatory role in IL-1β signaling in RASFs and suggests CB2 as a potential therapeutic target in the management of pain and inflammation in RA.


Disclosure: S. Fechtner, None; A. K. Singh, None; S. Ahmed, None.

To cite this abstract in AMA style:

Fechtner S, Singh AK, Ahmed S. Characterization of the Role of Endocannabinoid System Using Jwh-133, a Selective Cannabinoid CB2 Receptor Agonist, in IL-1β-Induced Inflammation in Human Rheumatoid Arthritis Synovial Fibroblasts [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/characterization-of-the-role-of-endocannabinoid-system-using-jwh-133-a-selective-cannabinoid-cb2-receptor-agonist-in-il-1%ce%b2-induced-inflammation-in-human-rheumatoid-arthritis-synovial-fibroblast/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-the-role-of-endocannabinoid-system-using-jwh-133-a-selective-cannabinoid-cb2-receptor-agonist-in-il-1%ce%b2-induced-inflammation-in-human-rheumatoid-arthritis-synovial-fibroblast/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology